Anitoa Systems has expanded its SARS-CoV-2 rapid nucleic acid test portfolio with the launch of two new kits to detect Delta and Omicron mutations.

The two kits include the research use only (RUO) SARS-CoV-2, Delta and Omicron kit, as well as the CE-IVD certified SARS-CoV-2 and Delta variant kit.

To test SARS-CoV-2 as well as its variants, the company integrates an in-house portable real-time polymerase chain reaction (qPCR) instrument, named Maverick, and its reverse transcription qPCR (RT-qPCR) reagent.

Anitoa Systems stated that the solution helps avoid the complex process of packing and shipping patient samples to a central laboratory along with the additional steps needed before running RT-qPCR.

According to the company, this helps to reduce cross-contamination risks and saves time.

By avoiding the degradation of viral RNAs that occurs while samples are being shipped, Anitoa’s portable device also reduces false-negative readings and provides more accurate results.

The solution allows patient samples, such as nasal or throat swabs, to be directly applied to the portable instrument on-site and removes the need to freeze, transport and thaw samples in a lab.

Anitoa Systems CEO Dr Zhimin Ding said: “As a key supplier of equipment and materials for detecting SAR-Cov-2, Anitoa is closely monitoring all current and emerging variants of this deadly virus to ensure that our test solutions are relevant to the need of the people combating this disease.”

The Maverick RT-qPCR device detects multiple gene targets in a single sample with a four-plex optical multiplexing subsystem. It takes approximately 45 minutes to deliver results.

Recently, Quidel confirmed that its Sofia SARS Antigen FIA and QuickVue At-Home OTC Covid-19 Test has the capability to detect new and emerging Covid-19 variants, such as Omicron.